ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
MWN-AI** Summary
In his recent letter to shareholders, John B. Payne, Chairman and CEO of ZIVO Bioscience, Inc. (OTCQB: ZIVO), highlighted the company’s pivotal progress and future opportunities in both human nutrition and animal health sectors. ZIVO, known for its proprietary algal cultures, has demonstrated significant advancements in providing natural antioxidant solutions and addressing pressing agricultural challenges, notably reducing antibiotic use in livestock while maintaining productivity.
Payne detailed that the past year marked astonishing scientific validation of ZIVO’s algae technology. A biochemical analysis revealed that ZIVO’s algae contains high levels of antioxidants, surpassing a competing product's performance. These findings enhance ZIVO's attractiveness as a partner for leading nutraceutical companies, and management anticipates entering into commercial agreements that would elevate human health revenues significantly.
In the realm of animal health, ZIVO is pioneering non-antibiotic solutions that strengthen animal immune systems to combat disease, validated through promising results in avian influenza studies. These successes have attracted interest from global animal health firms and have laid the groundwork for expanding their addressable market, particularly within companion animals.
Financially, ZIVO is targeting the booming multibillion-dollar markets for antibiotic-free livestock feed and veterinary supplements. The company is strategically positioned to capitalize on growing demand for natural products in response to regulatory pressures against antibiotic overuse and consumer preferences for healthier animal products.
Furthermore, Payne emphasized management’s commitment to transparency as they work to enhance shareholder value, aiming to navigate liquidity challenges through capital raising initiatives. With an optimistic outlook, ZIVO is poised for substantial growth and value creation driven by both the human nutrition and animal health markets.
MWN-AI** Analysis
ZIVO Bioscience (OTCQB: ZIVO) is positioned at a promising intersection of human nutrition and animal health, as articulated in Chairman John B. Payne's recent shareholder letter. With the company reporting significant breakthroughs in its proprietary algae-based products, especially their proven antioxidant properties, ZIVO stands to gain traction in the expanding nutraceutical market. The successful independent analysis of ZIVO's algae, which demonstrated superior levels of antioxidants compared to competitors, not only validates its product but also underscores a pivotal competitive advantage.
Investors should note the strategic importance of the current market dynamics. The global movements towards natural, non-antibiotic solutions in animal health reflect a regulatory shift and changing consumer preferences. As ZIVO targets the antibiotic-free livestock feed sector, which is projected to grow significantly in the coming years, the opportunity for revenue growth appears substantial.
Moreover, the company's proactive outreach with major industry players indicates robust interest and potential for future commercial engagements that could drive revenue in the short- to medium-term. Given the extensive market valuations for both poultry and companion animal sectors, ZIVO is tapping into a lucrative base.
However, potential investors must be cautious. While ZIVO shows promise, it also faces liquidity challenges that could hinder its growth trajectory. Raising capital will be critical in the near future. Also, the volatility typical of biotech stocks can result in high levels of investment risk.
In conclusion, ZIVO Bioscience has a compelling value proposition with its innovative algae-derived products and a clear strategy targeting high-growth markets. Given this favorable outlook coupled with near-term commercialization prospects, investors may consider positioning in ZIVO, while remaining vigilant of the inherent risks that accompany biotech investments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ZIVO Bioscience, Inc. (OTCQB: ZIVO) , a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne.
Dear Fellow Shareholders,
I am pleased to provide you with this important update on the significant progress by ZIVO Bioscience and a review of our exciting future direction. Quite simply, this past year has been one of the most pivotal in our history. Our proprietary algae platform has delivered breakthrough results that position ZIVO at the forefront of two rapidly growing markets – human nutrition and animal health – while addressing one of agriculture’s most pressing global challenges: reducing antibiotic use at cost parity and without compromising animal productivity.
Breakthrough Scientific Validation
Over the past year, we have achieved remarkable validation of our algae technology that we believe fundamentally positions ZIVO as a leader in natural antioxidant solutions. At the request of a prospective major customer, an independent biochemical analysis was conducted on our algae product. The results exceeded our expectations: our algae contains substantial levels of key antioxidants, including Superoxide Dismutase (SOD) and catalase, as well as a rich profile of vitamins, carotenoids, and proteins.
Most notably, this preliminary study demonstrated that our algae had, on average, nearly double the activity of SOD in a side-by-side comparison to a competing algae-based product. Together with its abundant beta-carotene and lutein, these exciting results position ZIVO's product as a powerful natural source of antioxidants.
We believe this breakthrough definitively sets us apart in the nutraceutical marketplace and positions us as an attractive partner for leading companies seeking validated, high-performance natural ingredients. We are presently in active discussions with major nutraceutical clients, and we anticipate significant commercial commitments in the near term that will materially increase our human health revenues.
Animal Health Market Leadership
Equally transformative are our advances in the animal health sector, where we believe our data has proven exceptionally compelling. Our algae culture provides critical ingredients in non-antibiotic animal feed formulations that dramatically boost animals' immune systems, helping to prevent or delay the onset of viral, bacterial, and parasitic diseases.
Our recent studies in poultry infected with avian influenza have been especially encouraging. In controlled university challenge trials, birds receiving our algae-derived immune modulator showed delayed transmission, lower viral shedding, and faster immune response compared to the control group. These outcomes demonstrate not only strong biological activity, but also real-world potential to slow the spread of one of the industry’s most devastating diseases.
This success has generated substantial interest across the industry. We have continued to be approached by global animal health companies, validating both the market demand and the superior performance of our algae technology. Additionally, with such excellent results demonstrated, we intend to negotiate with major companion animal product companies, expanding our addressable market significantly.
Massive Market Opportunity
By addressing the urgent need for natural, non-antibiotic solutions, ZIVO is targeting some of the fastest-growing and highest-margin segments in animal health. In fact, the markets we are targeting represent multibillion-dollar opportunities:
U.S. and Global Market Scale Through 2030
The global animal feed market was valued at $465.65 billion in 2024 and is projected to reach $705.15 billion by 2034 1 . Within this broader market, the antibiotic-free livestock feed segment was valued at $4.5 billion in 2024 and is forecasted to grow at an exceptional 8.2% CAGR to reach $8.9 billion by 2033 2 .
Chicken-Specific Opportunities: Given our successful data collection in chickens, the poultry market presents exceptional near-term opportunities. The global poultry vaccines market is valued at $2.3 billion in 2023 with projections reaching $4.2 billion by 2032, growing at rates of 7.1% CAGR 3 . The U.S. poultry vaccines market specifically is expected to grow from $662.6 million in 2024 to $971.3 million by 2030 4 .
Major Husbandry Animals: Beyond poultry, the swine vaccines market was estimated at $1.75 billion in 2024 and is projected to reach $2.41 billion by 2030 5 . The broader livestock vaccines market was valued at $6.01 billion in 2024 and is projected to grow to $9.80 billion by 2032 6 .
Companion Animal Market: The companion animal vaccines market represents additional significant potential, valued at $5.43 billion in 2024 and projected to grow to $8.71 billion by 2032 7 . The pet supplements market shows even stronger growth potential, with the U.S. market alone exceeding $2.7 billion annually 8 .
Natural Immune System Boosters
The market for all-natural products that dramatically boost animals' immune systems represents a vast and rapidly growing marketplace. The veterinary supplements market is projected to reach $15.2 billion by 2031 at a 6.9% CAGR 9 , while the global animal feed supplements market reached $38.20 billion in 2024 and is expected to reach $58.96 billion by 2032 10 .
Strategic Market Position and Timing
We believe the convergence of regulatory pressure against antibiotic overuse, consumer demand for natural products, and our scientifically validated superior performance creates an exceptional market opportunity. With regulatory agencies increasingly restricting antibiotic use in livestock production and consumers demanding antibiotic-free animal products, ZIVO is positioned at the center of this industry transformation.
Management and Board Commitment
Finally, I want to emphasize that we have decided it is time to redouble our efforts to help the world understand what ZIVO does and recognize our unique investment opportunity. Over the past year, both the board and I have personally invested in the Company. We believe this demonstrates our deep conviction that today’s share price undervalues our scientific breakthroughs, expanding market opportunities, and pending commercial agreements that we believe will drive long-term shareholder value.
Looking Ahead
With complementary growth engines in human nutrition and animal health, ZIVO is uniquely positioned to deliver solutions to global health and agricultural challenges while creating lasting value for our shareholders. We are entering an exciting phase of execution and growth. While ZIVO continues to face liquidity challenges, we are optimistic we can overcome those through capital raising efforts. Further, we expect the nutraceutical market to provide significant near-term growth from new product commitments, while our animal health initiatives provide exceptional long-term opportunities in markets experiencing urgent global demand. Our natural algae technology addresses one of the most pressing challenges in modern agriculture: reducing antibiotic dependence while maintaining and enhancing animal health and productivity.
Together, these parallel paths in human nutrition and animal health give us confidence in advancing our mission to deliver safe, effective, and science-backed natural solutions. With our superior antioxidant performance now demonstrated, compelling commercial terms being negotiated, and multiple major industry players actively engaging with us, ZIVO is positioned for substantial growth and value creation.
In addition, there are several studies underway that have the potential to significantly impact the market for our products, our competitive position and our long-term growth trajectory. Although the confidential nature of this work precludes any further commentary at this time, I look forward to sharing more detail as soon as we are able.
On behalf of the entire ZIVO team, I want to thank you for your continued support and belief in our vision. We remain committed to transparency, execution, and delivering exceptional shareholder value as we move forward.
Sincerely,
John B. Payne
Chairman, President and Chief Executive Officer
ZIVO Bioscience, Inc.
About ZIVO Bioscience
ZIVO Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
Forward Looking Statements
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected timeframe for results of future studies. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes there is a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our preclinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials; our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this news release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250910182550/en/
ZIVO Bioscience
Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130
kmarchiando@zivobioscience.com
Alliance Advisors IR
Tirth T. Patel
(212) 201-6614
tpatel@allianceadvisors.com
FAQ**
How does ZIVO Bioscience Inc. (ZIVO) plan to leverage its proprietary algae technology to differentiate itself in the competitive human nutrition and animal health markets?
What specific measures is ZIVO Bioscience Inc. (ZIVO) implementing to address potential liquidity challenges while pursuing new commercial commitments and partnerships?
Can ZIVO Bioscience Inc. (ZIVO) provide more details on the anticipated commercial agreements with major clients and how these will impact projected revenue growth?
How does ZIVO Bioscience Inc. (ZIVO) intend to navigate regulatory pressures and consumer demand for non-antibiotic solutions in order to capitalize on the multibillion-dollar market opportunities it targets?
**MWN-AI FAQ is based on asking OpenAI questions about Zivo Bioscience Inc. (OTC: ZIVO).
NASDAQ: ZIVO
ZIVO Trading
-23.56% G/L:
$6.5965 Last:
5,680 Volume:
$8.10 Open:
